Olema Pharmaceuticals - OLMA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.43
  • Forecasted Upside: 97.32%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$10.86
▼ -0.69 (-5.97%)

This chart shows the closing price for OLMA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Olema Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OLMA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OLMA

Analyst Price Target is $21.43
▲ +97.32% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Olema Pharmaceuticals in the last 3 months. The average price target is $21.43, with a high forecast of $28.00 and a low forecast of $18.00. The average price target represents a 97.32% upside from the last price of $10.86.

This chart shows the closing price for OLMA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 8 investment analysts is to buy stock in Olema Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/17/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/15/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/2/2024The Goldman Sachs GroupInitiated CoverageBuy$24.00Low
2/22/2024Capital One FinancialReiterated RatingOverweightLow
1/30/2024CitigroupInitiated CoverageBuy$20.00Low
10/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$28.00Low
9/15/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$16.00 ➝ $19.00Low
9/6/2023OppenheimerReiterated RatingOutperform ➝ Outperform$21.00Low
9/5/2023HC WainwrightBoost TargetBuy ➝ Buy$22.00 ➝ $28.00Low
8/10/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$14.00 ➝ $16.00Low
8/9/2023HC WainwrightBoost TargetBuy ➝ Buy$17.00 ➝ $22.00Low
8/9/2023Credit Suisse GroupBoost TargetOutperform ➝ Outperform$16.00 ➝ $18.00Low
7/20/2023OppenheimerInitiated CoverageOutperform$21.00Low
5/12/2023Capital One FinancialBoost Target$16.00 ➝ $20.00Low
5/10/2023HC WainwrightLower Target$15.00 ➝ $14.00Low
5/5/2023Capital One FinancialInitiated CoverageOverweight$16.00Low
4/26/2023Lifesci CapitalReiterated RatingOutperformLow
3/10/2023Credit Suisse GroupLower TargetOutperform$12.00 ➝ $11.00Low
3/10/2023HC WainwrightBoost TargetBuy$12.00 ➝ $15.00Low
2/22/2023Credit Suisse GroupInitiated CoverageOutperform$12.00Low
7/6/2022Canaccord Genuity GroupReiterated RatingBuy$16.00N/A
6/9/2022HC WainwrightUpgradeNeutral ➝ Buy$12.00Medium
2/28/2022HC WainwrightInitiated CoverageNeutralMedium
6/21/2021Lifesci CapitalReiterated RatingOutperformHigh
12/14/2020JPMorgan Chase & Co.Initiated CoverageOverweight$52.00High
12/14/2020Jefferies Financial GroupInitiated CoverageBuy$70.00High
12/14/2020CowenInitiated CoverageOutperformHigh
(Data available from 4/14/2019 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/17/2023
  • 4 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
10/17/2023
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/16/2023
  • 5 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
12/16/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/15/2024
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/14/2024
  • 13 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
3/15/2024
  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/14/2024

Current Sentiment

  • 4 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Olema Pharmaceuticals logo
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $10.86
Low: $10.64
High: $11.73

50 Day Range

MA: $12.90
Low: $10.51
High: $16.62

52 Week Range

Now: $10.86
Low: $3.53
High: $17.79

Volume

681,923 shs

Average Volume

994,709 shs

Market Capitalization

$607.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Olema Pharmaceuticals?

The following Wall Street research analysts have issued research reports on Olema Pharmaceuticals in the last year: Capital One Financial Co., Citigroup Inc., Credit Suisse Group AG, HC Wainwright, JPMorgan Chase & Co., Lifesci Capital, Oppenheimer Holdings Inc., and The Goldman Sachs Group, Inc..
View the latest analyst ratings for OLMA.

What is the current price target for Olema Pharmaceuticals?

7 Wall Street analysts have set twelve-month price targets for Olema Pharmaceuticals in the last year. Their average twelve-month price target is $21.43, suggesting a possible upside of 97.3%. HC Wainwright has the highest price target set, predicting OLMA will reach $28.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $18.00 for Olema Pharmaceuticals in the next year.
View the latest price targets for OLMA.

What is the current consensus analyst rating for Olema Pharmaceuticals?

Olema Pharmaceuticals currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OLMA will outperform the market and that investors should add to their positions of Olema Pharmaceuticals.
View the latest ratings for OLMA.

What other companies compete with Olema Pharmaceuticals?

How do I contact Olema Pharmaceuticals' investor relations team?

Olema Pharmaceuticals' physical mailing address is 512 2ND STREET 4TH FLOOR, SAN FRANCISCO CA, 94107. The company's listed phone number is 650-243-5555 and its investor relations email address is [email protected]. The official website for Olema Pharmaceuticals is www.olema.com. Learn More about contacing Olema Pharmaceuticals investor relations.